Amneal Pharmaceuticals, Inc. (AMRX) earnings date
Feb 26, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 35 days, typically, give or take 12 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Nov 3, 2026 | before open | 34 | 8-K |
| Q2 FY2026 | Thu, Jul 30, 2026 | before open | 30 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Fri, Feb 27, 2026 | before open | 58 | 8-K |
| Q3 FY2025 | Thu, Oct 30, 2025 | before open | 30 | 8-K |
| Q2 FY2025 | Tue, Aug 5, 2025 | before open | 36 | 8-K |
| Q1 FY2025 | Fri, May 2, 2025 | before open | 32 | 8-K |
| Q4 FY2024 | Fri, Feb 28, 2025 | before open | 59 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 AMNEAL REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS – Q3 2026 Net Revenue of $863 million; GAAP Net Loss of $22 million; Diluted Loss per Share of $(0.06) – – Adjusted EBITDA of $207 million; Adjusted Diluted EPS of $0.26 – – Updating 2026 Full Year Guidance – BRIDGEWATER, NJ, November 3, 2026 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended September 30, 2026." exhibit |
| Q3 FY2026 | "“Amneal delivered another quarter of strong, broad-based performance, enabling us to increase our 2026 guidance once more." exhibit |
| Q3 FY2026 | "Adjusted EBITDA in the third quarter of 2026 was $207 million, an increase of 30% compared to the third quarter of 2025, reflecting higher revenue, higher gross profit, and lower operating expenses." exhibit |
| Q3 FY2026 | "Please refer to the “Non-GAAP Financial Measures” section and the accompanying GAAP to non-GAAP reconciliation tables for more information. 1 Updating 2026 Full Year Guidance We are increasing full year 2026 guidance for net revenue, adjusted EBITDA, and adjusted diluted EPS." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS – Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18 – – Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 – – Raising 2026 Full Year Guidance – – Successful Debt Repricing in July Reduces Interest Cost – BRIDGEWATER, NJ, July 30, 2026 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the second quarter ended June 30, 2026." exhibit |
| Q2 FY2026 | "This robust first-half performance gives us confidence to raise our full-year 2026 guidance for the second time this year." exhibit |
| Q2 FY2026 | "As we look ahead to the remainder of 2026, 2027 and beyond, we remain highly confident in Amneal’s outlook and the breadth and durability of the opportunities across our portfolio,” said Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal." exhibit |
| Q2 FY2026 | "Net income attributable to Amneal Pharmaceuticals, Inc. was $58 million in the second quarter of 2026 compared to net income of $22 million in the second quarter of 2025, an increase of 157%, as higher revenue and gross profit, lower interest expense, and a lower tax provision more than offset increased SG&A expense." exhibit |
| Q2 FY2026 | "The repricing is expected to close as early as August 3, 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/AMRX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/AMRX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/AMRX/"><img src="https://veritasdata.dev/embed/AMRX.svg" alt="AMRX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/AMRX/)
Script
<script async src="https://veritasdata.dev/embed/AMRX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/AMRX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.